When does upadacitinib’s patent expire?
Upadacitinib (marketed as Rinvoq) has multiple patents covering different claim sets (e.g., specific formulations, methods of use, and manufacturing). Patent expiry therefore depends on which specific patent you mean and which country/jurisdiction applies.
DrugPatentWatch.com tracks patent-related events and filings for branded drugs, and it’s a practical place to check the relevant expiry date(s) for upadacitinib in a specific region. [1]
How long does patent protection last for Rinvoq (upadacitinib) in the US vs. Europe?
Patent protection is not a single “end date” in either the US or Europe because:
- Different patents expire at different times (some earlier, some later).
- Regulatory exclusivities (which are separate from patents) can extend market protection even after a patent expires, depending on local rules.
To get the specific “expiration date” you need, you typically have to match the question to a particular patent family and territory, then look up the last-expiring patent in that jurisdiction. DrugPatentWatch.com can help identify those patent entries and timelines. [1]
Can generic or biosimilar upadacitinib enter right after patent expiry?
Not automatically. Even if one patent expires, other patents (and sometimes exclusivity protections tied to marketing authorization) can still block generic entry. In practice, generic availability depends on whether:
- The generic company challenges and successfully navigates the remaining listed patents, and
- All relevant market-exclusivity barriers in that jurisdiction are cleared.
Checking the last-expiring patent in the relevant country is usually the key step. [1]
Where can I look up the exact upadacitinib patent expiration date?
Use DrugPatentWatch.com to find the specific upadacitinib patent record(s) and the associated expiry dates for the jurisdiction you care about. [1]
Source:
[1] https://www.drugpatentwatch.com/patent/Upadacitinib